Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator ...

Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision ...

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Biotechnology company Atavistik Bio announced Thursday that it has entered into a research collaboration with Pfizer, Inc. (PFE) to ...

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), The Home ...